Cargando…

The Nephrotoxicity of Drugs Used in Causal Oncological Therapies

In recent years, a dynamic development of oncology has been observed, resulting from the increasingly frequent occurrence of neoplasms and therefore, increasing population of patients. The most effective form of therapy for cancer patients is complex multidisciplinary specialized disease management,...

Descripción completa

Detalles Bibliográficos
Autores principales: Hałka, Janusz, Spaleniak, Sebastian, Kade, Grzegorz, Antosiewicz, Stefan, Sigorski, Dawid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776938/
https://www.ncbi.nlm.nih.gov/pubmed/36547174
http://dx.doi.org/10.3390/curroncol29120760
_version_ 1784855981780369408
author Hałka, Janusz
Spaleniak, Sebastian
Kade, Grzegorz
Antosiewicz, Stefan
Sigorski, Dawid
author_facet Hałka, Janusz
Spaleniak, Sebastian
Kade, Grzegorz
Antosiewicz, Stefan
Sigorski, Dawid
author_sort Hałka, Janusz
collection PubMed
description In recent years, a dynamic development of oncology has been observed, resulting from the increasingly frequent occurrence of neoplasms and therefore, increasing population of patients. The most effective form of therapy for cancer patients is complex multidisciplinary specialized disease management, including nephro-oncology care. Different forms of renal function impairment are frequently diagnosed in cancer patients. They are caused by different co-morbidities existing before starting the oncologic treatment as well as the direct undesirable effects of this therapy which may cause temporary or irreversible damage of the urinary system—especially kidneys. According to different therapeutic programs, in such cases the degree of renal damage is often crucial for the possibility of further anti-cancer treatment. Medical personnel responsible for delivering care to oncology patients should be properly educated on current methods of prevention and treatment of renal complications resulting from anti-cancer therapy. The development of oncologic medicines design, including especially immuno-oncological agents, obliges us to learn new patomechanisms determining potential adverse effects, including renal complications. This publication is focused on the most important undesirable nephrotoxic effects of the frequently used anti-cancer drugs.
format Online
Article
Text
id pubmed-9776938
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97769382022-12-23 The Nephrotoxicity of Drugs Used in Causal Oncological Therapies Hałka, Janusz Spaleniak, Sebastian Kade, Grzegorz Antosiewicz, Stefan Sigorski, Dawid Curr Oncol Review In recent years, a dynamic development of oncology has been observed, resulting from the increasingly frequent occurrence of neoplasms and therefore, increasing population of patients. The most effective form of therapy for cancer patients is complex multidisciplinary specialized disease management, including nephro-oncology care. Different forms of renal function impairment are frequently diagnosed in cancer patients. They are caused by different co-morbidities existing before starting the oncologic treatment as well as the direct undesirable effects of this therapy which may cause temporary or irreversible damage of the urinary system—especially kidneys. According to different therapeutic programs, in such cases the degree of renal damage is often crucial for the possibility of further anti-cancer treatment. Medical personnel responsible for delivering care to oncology patients should be properly educated on current methods of prevention and treatment of renal complications resulting from anti-cancer therapy. The development of oncologic medicines design, including especially immuno-oncological agents, obliges us to learn new patomechanisms determining potential adverse effects, including renal complications. This publication is focused on the most important undesirable nephrotoxic effects of the frequently used anti-cancer drugs. MDPI 2022-12-08 /pmc/articles/PMC9776938/ /pubmed/36547174 http://dx.doi.org/10.3390/curroncol29120760 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Hałka, Janusz
Spaleniak, Sebastian
Kade, Grzegorz
Antosiewicz, Stefan
Sigorski, Dawid
The Nephrotoxicity of Drugs Used in Causal Oncological Therapies
title The Nephrotoxicity of Drugs Used in Causal Oncological Therapies
title_full The Nephrotoxicity of Drugs Used in Causal Oncological Therapies
title_fullStr The Nephrotoxicity of Drugs Used in Causal Oncological Therapies
title_full_unstemmed The Nephrotoxicity of Drugs Used in Causal Oncological Therapies
title_short The Nephrotoxicity of Drugs Used in Causal Oncological Therapies
title_sort nephrotoxicity of drugs used in causal oncological therapies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776938/
https://www.ncbi.nlm.nih.gov/pubmed/36547174
http://dx.doi.org/10.3390/curroncol29120760
work_keys_str_mv AT hałkajanusz thenephrotoxicityofdrugsusedincausaloncologicaltherapies
AT spaleniaksebastian thenephrotoxicityofdrugsusedincausaloncologicaltherapies
AT kadegrzegorz thenephrotoxicityofdrugsusedincausaloncologicaltherapies
AT antosiewiczstefan thenephrotoxicityofdrugsusedincausaloncologicaltherapies
AT sigorskidawid thenephrotoxicityofdrugsusedincausaloncologicaltherapies
AT hałkajanusz nephrotoxicityofdrugsusedincausaloncologicaltherapies
AT spaleniaksebastian nephrotoxicityofdrugsusedincausaloncologicaltherapies
AT kadegrzegorz nephrotoxicityofdrugsusedincausaloncologicaltherapies
AT antosiewiczstefan nephrotoxicityofdrugsusedincausaloncologicaltherapies
AT sigorskidawid nephrotoxicityofdrugsusedincausaloncologicaltherapies